Can-Fite Biopharma Ltd (CANF) said Tuesday that the Korean Intellectual Property Office has issued a patent for its lead drug candidate Piclidenoson (CF101) to treat psoriasis.
Can-Fite has two distribution agreements in Korea. One is with Kwang Dong Pharmaceutical for Piclidenoson to treat rheumatoid arthritis, and the other is with Chong Kun Dang for Namodenoson in the treatment of liver cancer.
“Korea is an important market for us, as evidenced by the two distribution agreements we already have there,” said Can-Fite CEO Pnina Fishman. “This patent may increase the value of a potential distribution deal in Korea for Piclidenoson in the treatment of psoriasis.”